Sorafenib in liver function impaired advanced hepatocellular carcinoma / 中国医学科学杂志(英文版)
Chinese Medical Sciences Journal
; (4): 7-14, 2014.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-242908
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To explore the efficacy and safty of sorafenib in Child-Pugh class B to class C hepatocellular carcinoma (HCC).</p><p><b>METHODS</b>In this three-center open-label study from November 2011 to May 2013, we randomly assigned 189 patients with advanced Child-Pugh class B or C HCC patients into two groups, one group with 95 patient to receive sorafenib (400 mg a time, twice a day) and the other group with 94 patients to receive best supportive care. The primary end points were progression-free survival and overall survival.</p><p><b>RESULTS</b>The median progression-free survival was 2.2 months and 1.9 months in the sorafenib group and best supportive care group respectively (Hazard ratio in the sorafenib group, 0.55; 95% confidence interval, 0.40-0.75; P=0.002). The median overall survival was 4.0 months and 3.5 months in the sorafenib group and best supportive care group respectively (Hazard ratio in the sorafenib group, 0.48; 95% confidence interval, 0.35-0.68; P<0.001). The main adverse effect of sorafenib was rash and acne of the skin (in 51.7% patients). The incidences of severe rash, diarrhea, and dry skin were 5.6%, 5.6%, and 2.2% in the sorafenib group. One patient reached partial response in the sorafenib group.</p><p><b>CONCLUSIONS</b>Sorafenib is safe in patients with liver function impaired advanced HCC. It is effective in terms of progression-free survival and overall survival compared with best supportive care. Liver functions are the important predictive factors.</p>
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
Neglected Diseases
/
SDG3 - Target 3.3 End transmission of communicable diseases
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
/
SDG3 - Target 3.2 Reduce avoidable death in newborns and children under 5
Health problem:
Target 3.2: Reduce avoidable death in newborns and children under 5
/
Diarrhea
/
Diarrhoeal Infections
/
Digestive System Diseases
/
Liver Cancer
/
Noncommunicable Diseases
Database:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Phenylurea Compounds
/
Mortality
/
Treatment Outcome
/
Niacinamide
/
Carcinoma, Hepatocellular
/
Disease-Free Survival
/
Cross-Over Studies
/
Therapeutic Uses
/
Drug Therapy
Type of study:
Controlled clinical trial
/
Prognostic study
Limits:
Adolescent
/
Adult
/
Aged
/
Aged, 80 and over
/
Female
/
Humans
/
Male
Language:
English
Journal:
Chinese Medical Sciences Journal
Year:
2014
Document type:
Article